Antonio Llombart-Cussac
Arnau de Vilanova Hospital, Valencia, Spain · Arnau de Vilanova Hospital, Valencia (Spain)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Antonio Llombart-Cussac as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:26 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT06382948 · Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.MedSIR · recruiting · Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer · principal investigator
- Ph2NCT06172127 · PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast CancerMedSIR · active not recruiting · HER2-positive Breast Cancer · principal investigator
- Ph2NCT05810870 · PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With EribulinMedSIR · active not recruiting · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer · principal investigator
- Ph2NCT04733118 · Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast CancerMedSIR · active not recruiting · Early Breast Cancer · principal investigator
- Ph2NCT04714619 · CB-103 Plus NSAI In Luminal Advanced Breast CancerMedSIR · terminated · Advanced Breast Cancer · principal investigator
- Ph2NCT04603183 · ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaLMedSIR · completed · Breast Cancer Metastatic · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 11:26 UTC. The ranking covers the 200 most relevant of 66 PubMed records, and a shared surname and initials can bring in a namesake. All 66 on PubMed
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.J Clin Oncol · 20171,369 citationsRCR 43.9
- 832 citationsRCR 35.3
- Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study.Ann Oncol · 2001525 citationsRCR 10.8
- 284 citationsRCR 8.2
- 241 citationsRCR 29.8
- Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.J Clin Oncol · 2009235 citationsRCR 4.9
- 231 citationsRCR 5.8
- Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial.Neuro Oncol · 2023221 citationsRCR 19.7
- Imlunestrant with or without Abemaciclib in Advanced Breast Cancer.N Engl J Med · 2025189 citationsRCR 43.2
- Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.J Clin Oncol · 2015187 citationsRCR 5.2